Valuation: Allergan plc

Capitalization 63.66B 54.62B 50.89B 47.35B 87.36B 5,483B 97.54B 615B 232B 2,571B 239B 234B 9,449B P/E ratio 2018
-8.76x
P/E ratio 2019 -11.9x
Enterprise value 80.96B 69.47B 64.72B 60.22B 111B 6,973B 124B 782B 295B 3,269B 304B 297B 12,017B EV / Sales 2018
4.24x
EV / Sales 2019 4.98x
Free-Float
99.9%
Yield 2018
2.15%
Yield 2019 1.55%
More valuation ratios * Estimated data
U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for Skinvive by Juvederm for the Improvement of Neck Appearance Jun. 30 CI
Allergan Aesthetics to Launch Three New Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training Feb. 12 CI
BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands) 24-10-18 CI
Allergan Aesthetics Announces the Launch of Its Next Generation Hydration Product: Skinmedica HA5 Hydra Collagen Replenish + Restore Hydrator 24-08-27 CI
Allergan Aesthetics Debuts Alle Payment Plans 24-06-27 CI
Allergan Aesthetics Announces the U.S. FDA Approval of JUVEDERM VOLUMA XC for Injection in the Temple Region to Improve Moderate to Severe Temple Hollowing in Adults over the Age of 21 24-03-05 CI
Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of Onabotulinumtoxina for the Treatment of Platysma Prominence 23-09-18 CI
Allergan Aesthetics Announces the Journal of Cosmetic Dermatology Publishes Data Demonstrating Patient Satisfaction with Natural-Looking Outcomes Following Treatment with OnabotulinumtoxinA (BotoX®? Cosmetic) 23-08-30 CI
Allergan plc Announces U.S. FDA Approval of SKINVIVE™ by JUVÉDERM® 23-05-15 CI
Allergan Aesthetics Announces the Highly Anticipated National Launch of Juvéderm® Volux™ Xc 23-01-18 CI
Allergan Aesthetics Announces the Launch of the Long-Awaited SkinMedica Even & Correct Collection 23-01-17 CI
Allergan Aesthetics to Present Data from Its Leading Aesthetic Portfolio At the 2022 American Society for Dermatologic Surgery Meeting 22-10-07 CI
Allergan Aesthetics Announces the Launch of SkinMedica Firm & Tone Lotion for Body 22-08-31 CI
More news
Manager TitleAgeSince
Director of Finance/CFO 55 2016-11-30
President 54 2020-05-07
Director TitleAgeSince
Director/Board Member 54 2020-05-07
Director/Board Member - 2020-05-07
Director/Board Member - 2020-05-07
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-.--%+1.73% - - 63.66B
+1.34%-2.69%-9.09%+139.83% 693B
+0.44%+4.33%+5.33%-6.04% 394B
-1.12%-1.66%+10.59%+26.54% 334B
-2.22%-5.55%-53.26%-1.90% 287B
+0.58%+0.66%-7.15%-21.43% 259B
-1.12%-4.09%-2.94%+12.40% 223B
-0.17%-1.49%-15.11%-7.23% 215B
-1.91%-4.08%-35.65%-13.41% 201B
-1.17%-0.17%-10.94%+20.88% 158B
Average -0.46%-1.40%-13.14%+16.63% 282.86B
Weighted average by Cap. -0.40%-1.59%-11.07%+35.84%
See all sector performances

Financials

2018 2019
Net sales 15.79B 13.55B 12.62B 11.74B 21.67B 1,360B 24.19B 152B 57.56B 637B 59.22B 57.99B 2,343B 16.09B 13.8B 12.86B 11.97B 22.08B 1,386B 24.65B 155B 58.66B 650B 60.35B 59.1B 2,388B
Net income -5.1B -4.37B -4.07B -3.79B -6.99B -439B -7.81B -49.22B -18.58B -206B -19.12B -18.72B -756B -5.27B -4.52B -4.21B -3.92B -7.23B -454B -8.08B -50.91B -19.22B -213B -19.77B -19.36B -782B
Net Debt 21.89B 18.78B 17.5B 16.28B 30.04B 1,885B 33.54B 211B 79.81B 884B 82.11B 80.41B 3,249B 17.3B 14.85B 13.83B 12.87B 23.75B 1,490B 26.52B 167B 63.09B 699B 64.91B 63.56B 2,568B
More financial data * Estimated data
Logo Allergan plc
Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.
Employees
-
More about the company